Unique ID issued by UMIN | UMIN000011483 |
---|---|
Receipt number | R000013440 |
Scientific Title | Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder: a rater-masked,randomized trial. |
Date of disclosure of the study information | 2013/08/14 |
Last modified on | 2017/02/15 11:36:41 |
Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder: a rater-masked,randomized trial.
Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder:randomized trial.
Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder: a rater-masked,randomized trial.
Aripiprazole versus duloxetine in combination with mirtazapine for treatment-resistant,major deressive disorder:randomized trial.
Japan |
major depressive disorder
Psychiatry |
Others
NO
The aim of study is to compare clinical efficacy and tolerability of aripiprazole versus duloxetine as combination treatment with mirtazapine in patients with resistant major depressive disorder.
Efficacy
Exploratory
Explanatory
Not applicable
Hamilton Raing Scale for Depression
discontimuation rate, remission rate, adverse events
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Duloxetine
Aripiprazole
18 | years-old | <= |
65 | years-old | > |
Male and Female
DSM-4-TR:MDD
Patients with treatment-resistant MDD: HAMD17>15:sufficient dose SSRI (ESC>15mg,PAR>30mg,SER>75mg,FLU>112,5mg) for more than 2 weeks. After that, the patients have no respose (HAMD17>15)to MIR 30mg/day for more than 2 weeks
Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder.
Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria
Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days)
Patients taking pimozide
Patients with allergies to escitalopram, duloxetine and aripiprazole
Patients with QT interval prolongation
Patients treated with ECT within the previous 6 months
Patients having severe physical disease
Patients who are pregnant or may become pregnant
Patients at significant risk of suicide (having a score >3 on HAM-D item 11)
Patients who had made suicide attempt within the past year
100
1st name | |
Middle name | |
Last name | Nakao Iwata |
Fujita Health University School of Medicine
Department of Psychiatry
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan
0562-93-9250
nakao@fujita-hu.ac.jp
1st name | |
Middle name | |
Last name | Taro Kishi |
Fujita Health University School of Medicine
Department of Psychiatry
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan
0562-93-9250
tarok@fujita-hu.ac.jp
Department of Psychiatry, Fujita Health University School of Medicine
Department of Psychiatry, Fujita Health University School of Medicine
Other
NO
2013 | Year | 08 | Month | 14 | Day |
Unpublished
Completed
2013 | Year | 08 | Month | 14 | Day |
2013 | Year | 08 | Month | 14 | Day |
2013 | Year | 08 | Month | 14 | Day |
2017 | Year | 02 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013440
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |